Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.


Related Content

Aveo’s Tivozanib Will Face Challenging Survival Data At ODAC Review
Preparing For Tivozanib Approval, Aveo Restructures With Staff Cuts
At Astellas R&D Day, Enzalutamide And In-house Tech In The Spotlight
Astellas Balks On Vibativ License, But Focus Shifts To Tivozanib And MDV3100
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
RCC Market Snapshot: In A Crowded Field, What's Next?
Bayer/Onyx’ Nexavar Approved For Kidney Cancer


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts